Zobrazeno 1 - 10 of 59 pro vyhledávání: '"David, Pugatch"'
1
Time to Endorse A Sensitive Method for Scoring Endoscopic Activity of Ulcerative Colitis in Clinical Research
Autor: Neeraj Narula, Shahin Merat, David Liu, David Pugatch, Walter Reinisch
Publikováno v: Journal of Crohn's and Colitis. 17:302-304
The endoscopic scoring of ulcerative colitis is routinely used for both individual patient management and as an endpoint in clinical trials. The most commonly used scoring system is the Mayo endoscopic subscore, which scores endoscopic disease activi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cfdd29b44774734761a795bc0c09dd8
https://doi.org/10.1093/ecco-jcc/jjac120
Zobrazit plný text záznamu
2
Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment
Autor: E.J. Gane, Thomas Marbury, Wei Liu, Haoyu Wang, David Pugatch, Jens Kort, Eric Lawitz, Federico J. Mensa, Richard A. Preston, Matthew P. Kosloski
Publikováno v: European Journal of Clinical Pharmacology. 75:217-226
This study characterized the effects of hepatic impairment on the pharmacokinetics and safety of glecaprevir and pibrentasvir, two direct-acting antivirals used for treatment of chronic HCV infection. HCV-negative subjects with normal hepatic functio
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a797c0020196d307743cffb39a7f5eda
https://doi.org/10.1007/s00228-018-2576-4
Zobrazit plný text záznamu
3
PTG-100, an Oral α4β7 Antagonist Peptide
Autor: Raj Bhandari, Rish K. Pai, Larry C. Mattheakis, David Pugatch, David Liu, Scott D. Lee, Nishit B. Modi, Brian Bressler, Bittoo Kanwar, Stefan Schreiber, Brian G. Feagan, Silvio Danese, Geert R. D'Haens, Richard Shames, William J. Sandborn, Suneel K. Gupta
Publikováno v: Gastroenterology, 161(6), 1853-1864.e10. W.B. Saunders Ltd
Background & Aims Oral therapies targeting the integrin α4β7 may offer unique advantages for the treatment of inflammatory bowel disease. We characterized the oral α4β7 antagonist peptide PTG-100 in preclinical models and established safety, phar
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f027461942f2d46565a584a390cf617
http://www.scopus.com/inward/record.url?scp=85117830253&partnerID=8YFLogxK
Zobrazit plný text záznamu
6
Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials
Autor: Brian Conway, Yaozhu J. Chen, Jason Grebely, Tania M. Welzel, Ashley Brown, Henning Kleine, Alessio Aghemo, Yang Lei, Francesco Negro, David Pugatch, Eric Lawitz, Tarik Asselah, Federico J. Mensa, Norbert Bräu, Massimo Puoti
Publikováno v: Liver International
Liver International (2019)
Background & aims Adequate adherence to hepatitis C virus (HCV) treatment is believed to be a key component of treatment success because non-adherence can potentially result in treatment failure and the emergence of resistant viral variants. This ana
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1da15bbd87b930276402e5d24de8a22a
http://publikationen.ub.uni-frankfurt.de/files/54300/liv.14266.pdf
Zobrazit plný text záznamu
7
Drug-Drug Interactions of Tacrolimus or Cyclosporine With Glecaprevir and Pibrentasvir in Healthy Subjects
Autor: Weihan Zhao, Federico J. Mensa, Armen Asatryan, Jens Kort, David Pugatch, Matthew P. Kosloski, Hong Li, Wei Liu
Publikováno v: Clinical pharmacology in drug development. 8(6)
A fixed-dose combination of glecaprevir and pibrentasvir is approved for treatment of chronic infection with hepatitis C virus (HCV) genotypes 1-6. Three phase 1 open-label studies were conducted in healthy volunteers to evaluate the potential for cl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::152ef07ff4038c7cca4ec6f71204b82e
https://pubmed.ncbi.nlm.nih.gov/30861340
Zobrazit plný text záznamu
8
Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects
Autor: Federico J. Mensa, Thomas Marbury, Michael G. Collins, Matthew P. Kosloski, Weihan Zhao, Wei Liu, Richard A. Preston, Jens Kort, David Pugatch
Publikováno v: Antimicrobial Agents and Chemotherapy. 62
Hepatitis C virus (HCV) infection is an independent risk factor for developing chronic renal impairment and end-stage renal disease. Limited treatment options are available for HCV genotype 2, 3, 5, and 6 infections in patients with an estimated glom
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c1d6b369fc7bdd3aa76b668d243ba98
https://doi.org/10.1128/aac.01990-17
Zobrazit plný text záznamu
9
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
Autor: David R. Nelson, Georgios Papatheodoridis, Eric Lawitz, Massimo Colombo, Norbert Bräu, Stanislas Pol, Ashley Brown, Christine Collins, Vincent Leroy, Christophe Moreno, Yang Lei, Eric M. Yoshida, Edward Gane, David Pugatch, Federico J. Mensa, Marcello Persico, Matthew P. Kosloski
Publikováno v: The New England journal of medicine. 377(15)
Chronic hepatitis C virus (HCV) infection is more prevalent among patients who have chronic kidney disease than among those who do not have the disease. Patients with chronic kidney disease who also have HCV infection are at higher risk for progressi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97af48a7094d4ba94f9b4519a7ba2865
https://pubmed.ncbi.nlm.nih.gov/29580661
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje